FDA Approves Standard-Changing Therapy Trialed at Siteman
June 25, 2025
June 25, 2025
ST. LOUIS, Missouri, June 25 -- The Siteman Cancer Center issued the following news:
* * *
FDA Approves Standard-Changing Therapy Trialed at Siteman
Immunotherapy Improves Survival of Patients with Locally Advanced Head and Neck Cancer
*
The Food and Drug Administration (FDA) has approved a new standard of care for certain locally advanced head and neck cancers -- the first change in standard-of-care therapy for affected patients i . . .
* * *
FDA Approves Standard-Changing Therapy Trialed at Siteman
Immunotherapy Improves Survival of Patients with Locally Advanced Head and Neck Cancer
*
The Food and Drug Administration (FDA) has approved a new standard of care for certain locally advanced head and neck cancers -- the first change in standard-of-care therapy for affected patients i . . .